MariMed (MRMD) Q2 EPS Jumps to Positive
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 07 2025
0mins
Source: NASDAQ.COM
Earnings Performance: MariMed reported a non-GAAP EPS of $0.40 for Q2 2025, surpassing analysts' expectations, while GAAP revenue fell short at $39.6 million, marking a 2% decrease from the previous year due to declining retail sales despite growth in wholesale.
Strategic Expansion and Innovation: The company is focusing on expanding into new markets like Delaware and Pennsylvania, enhancing product innovation with new cannabis offerings, and shifting its strategy towards branded wholesale distribution, although retail sales have seen a decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
